Next Article in Journal
Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System
Next Article in Special Issue
Development and Evaluation of Physiologically Based Pharmacokinetic Drug–Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations
Previous Article in Journal
Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies
Previous Article in Special Issue
Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing
 
 
Article

Article Versions Notes

Pharmaceutics 2019, 11(11), 566; https://doi.org/10.3390/pharmaceutics11110566
Action Date Notes Link
article xml file uploaded 31 October 2019 13:34 CET Original file -
article xml uploaded. 31 October 2019 13:34 CET Update https://www.mdpi.com/1999-4923/11/11/566/xml
article pdf uploaded. 31 October 2019 13:34 CET Version of Record https://www.mdpi.com/1999-4923/11/11/566/pdf
article supplementary file uploaded. 31 October 2019 13:34 CET - https://www.mdpi.com/1999-4923/11/11/566#supplementary
article html file updated 31 October 2019 18:04 CET Original file -
article html file updated 27 November 2019 15:33 CET Update -
article html file updated 14 February 2020 05:37 CET Update -
article html file updated 20 July 2022 00:33 CEST Update https://www.mdpi.com/1999-4923/11/11/566/html
Back to TopTop